Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
58,081
result(s) for
"Biotechnology - economics"
Sort by:
GM food systems and their economic impact
This book adopts a methodical approach to provide a novel exploration of the effects of GM crops on global economy, as well as examining the links between GM and food security at global and regional levels. The environmental implications of GM are also considered, by comparing pesticide use and efficiency in GM and non-GM countries.
eBook
Patient-focused network integration in biopharma : strategic imperatives for the years ahead
\"Preface This book started out as an interesting set of conversations with some very insightful and intelligent people. For twenty-five years, I've studied supply chains in almost every industry, including oil and gas, automotive, electronics, industrial production, and even financial services. And every time I met with executives, I met with the same statements: \"We're different-- you don't understand.\" But in the end, after spending enough time with these executives, it became clear that the same principles of supply chain management applied. Perhaps a different context, different terminology, but in the end, the same rules applied. When I started dabbling in healthcare, I originally encountered the same sets of objections. \"Healthcare is different,\" I would hear, \"After all, you have to consider the patient.\" But as I spent more and more time with healthcare executives, I only rarely heard the patient mentioned in the discussion. More often than not, the discussion focused on compliance, reimbursement, diagnosis-related groups (DRGs), and other terms that had very little to do with patient care. And as I studied the industry more, it became clear that organizations in the healthcare value chain, from the patient through hospitals, wholesalers, through insurance payers, manufacturers, and finally research and development (R&D), were not very well connected at all\"-- Provided by publisher.
Book
TRYing to evaluate production costs in microbial biotechnology
Microbial fermentations are widely used for the production of chemicals used as pharmaceuticals, food ingredients, materials, solvents, and biofuels.Technoeconomic analysis of a given fermentation process is important to perform before scaling the process to levels that enable commercial production.Titer, rate, and yield (TRY) of the fermentation process are key metrics that are used for technoeconomic analysis.TRY metrics have different impacts on the technoeconomic analysis, and it is important to be aware of these differences.
Microbial fermentations offer the opportunity to produce a wide range of chemicals in a sustainable fashion, but it is important to carefully evaluate the production costs. This can be done on the basis of evaluation of the titer, rate, and yield (TRY) of the fermentation process. Here we describe how the three TRY metrics impact the technoeconomics of a microbial fermentation process, and we illustrate the use of these for evaluation of different processes in the production of two commodity chemicals, 1,3-propanediol (PDO) and ethanol, as well as for the fine chemical penicillin. On the basis of our discussions, we provide some recommendations on how the TRY metrics should be reported when new processes are described.
Microbial fermentations offer the opportunity to produce a wide range of chemicals in a sustainable fashion, but it is important to carefully evaluate the production costs. This can be done on the basis of evaluation of the titer, rate, and yield (TRY) of the fermentation process. Here we describe how the three TRY metrics impact the technoeconomics of a microbial fermentation process, and we illustrate the use of these for evaluation of different processes in the production of two commodity chemicals, 1,3-propanediol (PDO) and ethanol, as well as for the fine chemical penicillin. On the basis of our discussions, we provide some recommendations on how the TRY metrics should be reported when new processes are described.
Journal Article
The business of healthcare innovation
\"The Business of Healthcare Innovation is a wide-ranging analysis of business trends in the manufacturing segment of the healthcare industry. It provides a thorough overview and introduction to the innovative sectors fueling improvements in healthcare: pharmaceuticals, biotechnology, platform technology, medical devices and information technology. For each sector, the book examines the basis and trends in scientific innovation, the business and revenue models pursued to commercialize that innovation, the regulatory constraints within which each sector must operate and the growing issues posed by more activist payers and consumers. Specific topics include market structure and competition, the economics and rationale of product development, pricing, sales and marketing, contract negotiations with buyers, alliances versus mergers, business strategies and prospects for growth. Written by professors of the Wharton School and industry executives, the book shows why healthcare sectors are such an important source of growth in any nation's economy\"--Provided by publisher.
Book
Exosome cancer diagnostic reaches market
The first blood-based cancer diagnostic to exploit free-floating exosomes became commercially available in the US on January 21. The launch of this liquid biopsy from Exosome Diagnostics of Cambridge, Massachusetts, marks a step towards maturity for the fledgling science of exosome biology. Investment has also begun to flow into the area: on January 7, Exosome Diagnostics raised $60 million in a Series B round, and shortly afterwards, Woburn, Massachusettsbased Codiak Biosciences, a company pursuing both diagnostic and therapeutic applications, closed a $61-million B round, taking to $92 million its total raise since its emergence last November. Fundamental questions about the biology of exosomes remain unanswered, however, and scale up for high-throughput diagnostics remains a work in progress. For use as therapeutics, the industrial-manufacturing challenges will be even greater. This will be the gating event for turning this into a broadly applicable platform, says Codiaks founding CEO Doug Williams.
Journal Article
For blood and money : billionaires, biotech, and the quest for a blockbuster drug
This book tells the little-known story of how an upstart biotechnology company created a one-in-a-million cancer drug, and how the core team - denied their share of the profits - went and did it again. In this epic saga of money and science, a veteran financial journalist explains how the invention of two of the biggest cancer drugs in history became (for their backers) two of the greatest Wall Street bets of all time. In the multibillion-dollar business of biotech, where pharmaceutical companies, the government, hedge funds, and venture capitalists have spent billions on funding, experimentation, and treatments, a single molecule can stop cancer in its tracks - and make the people who find that rare molecule astonishingly rich. This book follows a small team at a biotech start-up in California, who have found one of these rare molecules. Their compound, known as a BTK inhibitor, seems to work on a vicious type of leukemia. When patients start rising from their hospice beds, the team knows they're onto something big. What follows is a story of genius, pathos, and drama, in which vivid characters navigate a world of corporate intrigue and ambiguous morality. The author's narrative immerses readers in the explosion of biotech start-ups. He describes the scientists, doctors, and investors who are risking everything to develop new, life-saving treatments, and introduces suffering patients for whom the stakes are life-or-death. A gripping nonfiction read, this book illustrates why it's so hard to bring new drugs to market, explains why they are so expensive, and examines how profit-driven venture capitalists are shaping the future of medicine. -- Adapted from publisher's description.
Book
The Sustainable Path to a Circular Bioeconomy
Circular bioeconomy is gaining prominence in academic, policy, and industry contexts, linking circular economy and bioeconomy agendas in service of sustainability. However, it is at risk of developing in narrow, unsustainable ways. A sustainable path to circular bioeconomies must embrace diverse expert and stakeholder input, multiple solutions, and noneconomic value.
Journal Article
Bacterial nanocellulose production and application: a 10-year overview
Production of bacterial nanocellulose (BNC) is becoming increasingly popular owing to its environmentally friendly properties. Based on this benefit of BNC production, researchers have also begun to examine the capacity for cellulose production through microbial hosts. Indeed, several research groups have developed processes for BNC production, and many studies have been published to date, with the goal of developing methods for large-scale production. During BNC bioproduction, the culture medium represents approximately 30 % of the total cost. Therefore, one important and challenging aspect of the fermentation process is identification of a new cost-effective culture medium that can facilitate the production of high yields within short periods of time, thereby improving BNC production and permitting application of BNC in the biotechnological, medical, pharmaceutical, and food industries. In this review, we addressed different aspects of BNC production, including types of fermentation processes and culture media, with the aim of demonstrating the importance of these parameters.
Journal Article
Oleaginous yeasts for sustainable lipid production—from biodiesel to surf boards, a wide range of “green” applications
A growing world population and a growing number of applications for vegetable oils are generating an increasing demand for these oils, causing serious environmental problems. A sustainable lipid production is then fundamental to address these problems. Oleaginous yeasts are a promising solution for sustainable lipid production, but, with the current knowledge and technology, they are still not a serious alternative in the market. In this review, the potential of these yeasts is highlighted and a discussion is made mainly focused on the economics of the oleaginous yeast oil production and identification of the key points to be improved to achieve lower production costs and higher income. Three main stages of the production process, where costs are higher, were identified. To render economically feasible the production of oils using oleaginous yeasts, a reduction in production costs must occur in all stages, lipid yields and productivities must be improved, and production must be targeted to high-value product applications.
Journal Article